Press Releases
Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam
Recro Pharma to Host Educational Symposium on Pain Management Options in Total Joint Replacements at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting
Recro Pharma Obtains $40.5 Million of Non-Dilutive Capital Through Expanded Credit Facility
Recro Pharma Announces Publication of Phase III IV Meloxicam Clinical Safety and Opioid Use Data in the Journal Clinical Pharmacology in Drug Development
Recro Pharma Announces New IV Meloxicam Data Publication in the Journal Regional Anesthesia & Pain Medicine
Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
Recro Pharma to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call and Webcast on February 19, 2019
Recro Pharma Announces Five-Year Manufacturing and Supply Agreement Between Novartis and Recro Gainesville
Recro Pharma Amends Athyrium Credit Facility
